Alfredo Guarino

Prof. Alfredo Guarino

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
AGAlfredo Guarino
Alfredo Guarino
SAShai Ashkenazi
Shai Ashkenazi
DGDominique Gendrel
Dominique Gendrel
AVAndrea Lo Vecchio
Andrea Lo Vecchio
RSRaanan Shamir
Raanan Shamir
HSHania Szajewska
Hania Szajewska

9 August 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
RCRoberto Berni Canani
Roberto Berni Canani
PCPia Cirillo
Pia Cirillo
Gianluca TerrinGianluca Terrin
Gianluca Terrin
LCLuisa Cesarano
Luisa Cesarano
Maria Immacolata SpagnuoloMaria Immacolata Spagnuolo
Maria Immacolata Spagnuolo
AGAlfredo Guarino
Alfredo Guarino
Objective To compare the efficacy of five probiotic preparations recommended to parents in the treatment of acute diarrhoea in children. Design Randomised controlled clinical trial in collaboration with family paediatricians over 12 months.Setting Primary care.Participants Children aged 3-36 months visiting a family paediatrician for acute diarrhoea.Intervention Children's parents were randomly assigned to receive written instructions to purchase a specific probiotic product: oral rehydration solution (control group); Lactobacillus rhamnosus strain GG; Saccharomyces boulardii; Bacillus clausii; mix of L delbrueckii var bulgaricus, Streptococcus thermophilus, L acidophilus, and Bifidobacterium bifidum; or Enterococcus faecium SF68. Main outcome measures Primary outcomes were duration of diarrhoea and daily number and consistency of stools. Secondary outcomes were duration of vomiting and fever and rate of admission to hospital. Safety and tolerance were also recorded. Results 571 children were allocated to intervention. Median duration of diarrhoea was significantly shorter (P<0.001) in children who received L rhamnosus strain GG (78.5 hours) and the mix of four bacterial strains (70.0 hours) than in children who received oral rehydration solution alone (115.0 hours). One day after the first probiotic administration, the daily number of stools was significantly lower (P<0.001) in children who received L rhamnosus strain GG and in those who received the probiotic mix than in the other groups. The remaining preparations did not affect primary outcomes. Secondary outcomes were similar in all groups. Conclusions Not all commercially available probiotic preparations are effective in children with acute diarrhoea. Paediatricians should choose bacterial preparations based on effectiveness data.Trial registration number Current Controlled Trials ISRCTN56067537.

1 March 2016 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
HSHania Szajewska
Hania Szajewska
RCRoberto Berni Canani
Roberto Berni Canani
AGAlfredo Guarino
Alfredo Guarino
IHIva Hojsak
Iva Hojsak
FIFlavia Indrio
Flavia Indrio
EPESPGHAN Working Group for Probiotics/Prebiotics
ESPGHAN Working Group for Probiotics/Prebiotics

1 April 2014 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
HSHania Szajewska
Hania Szajewska
AGAlfredo Guarino
Alfredo Guarino
IHIva Hojsak
Iva Hojsak
FIFlavia Indrio
Flavia Indrio
SKSanja Kolacek
Sanja Kolacek
ZWZvi Weizman
Zvi Weizman

1 November 1997 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
AGAlfredo Guarino
Alfredo Guarino
RCRoberto Berni Canani
Roberto Berni Canani
Maria Immacolata SpagnuoloMaria Immacolata Spagnuolo
Maria Immacolata Spagnuolo
FAFabio Albano
Fabio Albano
LBLinda Di Benedetto
Linda Di Benedetto

19 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EBEugenia Bruzzese
Eugenia Bruzzese
MCMaria Luisa Callegari
Maria Luisa Callegari
VRValeria Raia
Valeria Raia
SVSara Viscovo
Sara Viscovo
RSRiccardo Scotto
Riccardo Scotto
AGAlfredo Guarino
Alfredo Guarino
Intestinal inflammation is a hallmark of cystic fibrosis (CF). Administration of probiotics can reduce intestinal inflammation and the incidence of pulmonary exacerbations. We investigated the composition of intestinal microbiota in children with CF and analyzed its relationship with intestinal inflammation. We also investigated the microflora structure before and after Lactobacillus GG (LGG) administration in children with CF with and without antibiotic treatment. The intestinal microbiota were analyzed by denaturing gradient gel electrophoresis (DGGE), real-time polymerase chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH). Intestinal inflammation was assessed by measuring fecal calprotectin (CLP) and rectal nitric oxide (rNO) production in children with CF as compared with healthy controls. We then carried out a small double-blind randomized clinical trial with LGG. Twenty-two children with CF children were enrolled in the study (median age, 7 years; range, 2–9 years). Fecal CLP and rNO levels were higher in children with CF than in healthy controls (184±146 µg/g vs. 52±46 µg/g; 18±15 vs. 2.6±1.2 µmol/L NO2−, respectively; P<0.01). Compared with healthy controls, children with CF had significantly different intestinal microbial core structures. The levels of Eubacterium rectale, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium catenulatum, and Faecalibacterium prausnitzii were reduced in children with CF. A similar but more extreme pattern was observed in children with CF who were taking antibiotics. LGG administration reduced fecal CLP and partially restored intestinal microbiota. There was a significant correlation between reduced microbial richness and intestinal inflammation. CF causes qualitative and quantitative changes in intestinal microbiota, which may represent a novel therapeutic target in the treatment of CF. Administration of probiotics restored gut microbiota, supporting the efficacy of probiotics in reducing intestinal inflammation and pulmonary exacerbations. ClinicalTrials.gov NCT 01961661